Related Experiment Video
Updated: Jan 16, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Combined Compression and Cooling Therapy for Taxane Chemotherapy-induced Peripheral Neuropathy in Lung Cancer
Yasuhiro Nakajima1,2, Kozo Kuribayashi3, Akio Tada1,2
1Division of Respiratory Medicine, Department of Internal Medicine, Society of St. Franciscan Himeji St. Mary's Hospital, Himeji, Japan.
Background/Aim:
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side-effect of taxane-based treatments. This study aimed to assess the efficacy and safety of a combined compression and cooling therapy for CIPN prevention in patients with lung cancer receiving taxane-containing regimens.
Patients And Methods:
We retrospectively analyzed 53 patients with advanced lung cancer treated with taxane-based chemotherapy between April 2021 and March 2023. Patients underwent compression therapy using surgical gloves and elastic stockings, combined with cooling gloves and foot ice pillows, during chemotherapy infusion.
Results:
CIPN incidence was 20.8%, with no cases of grade ≥3 neuropathy. Paclitaxel and nab-paclitaxel showed lower CIPN rates (19.0% and 15.0%, respectively) compared to docetaxel (33.3%). No patients required chemotherapy dose reductions, and adverse events related to the therapy were mild and reversible.
Conclusion:
Combined compression and cooling therapy appears to be a safe, feasible, and non-pharmacologic strategy for reducing CIPN in taxane-treated lung cancer patients. Further prospective validation is warranted.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Drugs that Stabilize Microtubules
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

